Stock Price Bolstered Mid-Session: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

Lloyd Doyle
October 13, 2017

Therefore 22% are positive. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $1.5. They now have a United States dollars 2 price target on the stock.

06/15/2016 - Infinity Pharmaceuticals, Inc. was downgraded to "equal weight" by analysts at Morgan Stanley. The stock of Infinity Pharmaceuticals Inc. Out of rating recommendations 0 have given the stock a Buy while 0 recommend the stock as Outperform.

05/07/2015 - Deutsche Bank began new coverage on Infinity Pharmaceuticals, Inc. giving the company a "buy" rating. Ameriprise Financial Inc. bought a new position in shares of Infinity Pharmaceuticals in the 2nd quarter worth approximately $130,000. (NASDAQ:INFI). 221,738 were accumulated by Element Capital Ltd Liability Com. (NASDAQ:INFI) or 28,896 shares. Days to cover decreased from 1.0 to 0.0 and the short interest percentage is 0.01% as of September 15. The SI to Kempharm Incorporated's float is 7.15%. INFI has analyst rating of 3.00 on scale of 1-5.

According to 12 analysts Oclaro Inc (NASDAQ:OCLR)'s price will reach at $12.58 during 52 weeks. It has underperformed by 77.66% the S&P500.

Investors sentiment decreased to 0.63 in 2017 Q2. Its down 0.11, from 0.74 in 2017Q1. That's a potential 2.04 increase relative to where Infinity Pharmaceuticals, Inc. 15 funds opened positions while 12 raised stakes. Fmr invested in 0% or 222,373 shares.

Currently Infinity Pharmaceuti (NASDAQ:INFI)'s shares owned by insiders are 1.6%, whereas shares owned by institutional owners are 71.6%. (NASDAQ:INFI) for 353,891 shares.

The stock's Average True Range (ATR) is 0.14. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has declined 60.96% since October 13, 2016 and is downtrending. Past 5 years growth of Infinity Pharmaceuti (NASDAQ:INFI) observed at 19.94%, looking forward for the next 5 years it has a strong prediction of 89.63% over growth. D E Shaw And Inc has invested 0% of its portfolio in Infinity Pharmaceuticals Inc. So far 25,429,810 shares have changed hands.

Technical traders may be staring at recent indicator levels on shares of Infinity Pharmaceuticals, Inc. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. It now has negative earnings. The Company develops small molecule drugs that target disease pathways for potential applications in oncology.

Infinity Pharmaceuticals, Inc. had its "neutral" rating reiterated by analysts at Wedbush. (NASDAQ:INFI) to report earnings on November, 8. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.12).

According to analysts Infinity Pharmaceuti (NASDAQ:INFI)'s minimum EPS for the current quarter is at $-0.22 and can go high up to $-0.18. About 61.01M shares traded or 3642.94% up from the average. (INFI) has a market cap of $74.17 million and over the last 12 months, Infinity Pharmaceuticals, Inc. It has underperformed by 77.66% the S&P500. Veritone, given 1 buy-equivalent recommendations, 0 sells and 0 holds. On Monday, August 10 the stock rating was upgraded by Zacks to "Hold". As per Tuesday, December 20, the company rating was reinitiated by Canaccord Genuity. (NASDAQ:INFI) on Thursday, February 25 with "Neutral" rating.

The stock is among the market's biggest gainers today.

Other reports by Iphone Fresh

Discuss This Article